Accessibility Menu
Amneal Pharmaceuticals logo

Amneal Pharmaceuticals(NASDAQ) AMRX

Current Price$17.93
Market Cap$5.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)+19%
5 Year+271%
1 Year+124%
1 Month+4%
Amneal Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 17.922026-07-24
Amneal Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.39%USD 17.852026-07-17
1 month+3.76%USD 17.272026-06-24
3 month+43.13%USD 12.522026-04-24
Year to date+42.22%USD 12.602025-12-31
1 year+124%USD 8.002025-07-24
3 year+485.62%USD 3.062023-07-25
5 year+271.01%USD 4.832021-07-23
Since inception+19.39%USD 15.012018-05-07

Amneal Pharmaceuticals Financials at a Glance

Market Cap

$5.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$3.05B

Net Income (TTM)

$122.36M

EPS (TTM)

$0.37

P/E Ratio

48.04

Dividend

$0.00

Beta (Volatility)

1.06 (Average)

Price

$17.93

Volume

33,825

Open

$18.11

Previous Close

$17.93

Daily Range

$17.83 - $18.19

52-Week Range

$7.67 - $18.39

Estimated Earnings Date

Jul 30, 2026

AMRX News

BuyAlert-Purple.png

Is Amneal Stock a Buy After Investment Firm Westshore Wealth Bought Over 1 Million Shares?

Robert IzquierdoNov 28, 2025
SellAlert-Blue.png

Amneal EVP Sells $1.6 Million in Shares as Stock Trades Near Multi-Year Highs

Jonathan PoncianoNov 21, 2025
Foolcom-Featured.png

Amneal (AMRX) Q2 EPS Jumps 56%

Motley Fool Markets TeamAug 5, 2025
2valuestocks

Why Shares of Amneal Pharmaceuticals Are Plunging Wednesday

James HalleyJul 5, 2023
Coronavirus patient 2

FDA: You Can Use Chloroquine to Treat COVID-19; EU Regulators: Not Just Yet

Brian Orelli, PhDApr 2, 2020
GettyImages-1146913659

Top Drug Stocks Under $5

David HaenMar 26, 2020
GettyImages-1161161804

Amneal Ramping Up Malaria Drug Production to Treat Coronavirus Patients

Mark PrvulovicMar 20, 2020
COVID-19 patient

Are Chloroquine and Hydrochloroquine Approved to Treat COVID-19?

Brian Orelli, PhDMar 20, 2020
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Amneal Pharmaceuticals

Amneal makes and sells many types of medicine people use every day. They help patients with brain and hormone health problems get the treatments they need. The company also delivers medical supplies to government hospitals and pharmacies.

Pills, Shots, and Branded Drugs

  • Affordable Medicines: Lower-cost generic versions of common drugs, injectable treatments, and biosimilars, which are near-copies of complex biological medicines.
  • AvKARE: Distribution services for medical products and pharmaceuticals primarily serving the U.S. government, military, and retail pharmacies.
  • Specialty Branded Products: Branded medications that focus on central nervous system disorders and hormone conditions like Parkinson’s disease and hypothyroidism.

Expanding the Medicine Cabinet

  • Agreed to acquire Kashiv BioSciences, LLC in April 2026 to increase its portfolio of complex medicines and clinical-stage products.
  • Entered a supply and distribution deal with MSN Laboratories Private Limited in April 2026 for the exclusive rights to a generic bladder treatment.
  • Resolved a majority of state and local government legal claims by activating a nationwide settlement for opioid-related litigation in January 2026.
  • Lowered the interest rate margins on its multi-billion dollar term loan through a repricing agreement in February 2026.

Control from Lab to Pharmacy

Amneal uses a vertically integrated model, which means it manages everything from its own research and development to manufacturing in the U.S. and India. This structure allows the company to produce a wide range of products, including complex liquids, inhalers, and skin patches.

Recent Financial Performance

  • Net income rose to $62.5 million in Q1 2026, a 412.5% increase from Q1 2025.
  • Operating income reached $133.5 million in Q1 2026, up from a loss of $10.7 million in Q1 2024.
  • Gross profit grew to $320.1 million in Q1 2026, up 25.1% from the previous year.
  • Free cash flow worsened to negative $42.6 million in Q1 2026, down from negative $10.9 million in Q1 2025.

Evolution of the Business

Amneal has transitioned from a standard generic drug maker into a diversified pharmaceutical firm with branded medicines and government supply contracts. This evolution reflects a strategy focused on specialized medical products and long-term distribution partnerships.

AI Generated • May 22, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

8,500

CEO

Chintu Patel, PhD; Chirag K. Patel, PhD

Website

www.amneal.com

Headquarters

Bridgewater, NJ 08807, US

AMRX Financials

Key Financial Metrics (TTM)

Gross Margin

38.66%

Operating Margin

11.80%

Net Income Margin

4.02%

Return on Equity

-144.72%

Return on Capital

15.87%

Return on Assets

3.46%

Earnings Yield

2.08%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

319.33M

Volume

33.83K

Avg. Volume

1.92M

Financials (TTM)

Gross Profit

$1.18B

Operating Income

$359.29M

EBITDA

$626.02M

Operating Cash Flow

$303.86M

Capital Expenditure

-$98.58M

Free Cash Flow

$205.28M

Cash & ST Invst.

$197.66M

Total Debt

$2.70B

Amneal Pharmaceuticals Performance Analysis

Amneal Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 2,212,304,0005.7%
20232023-12-31USD 2,393,607,0008.2%
20242024-12-31USD 2,793,957,00016.7%
20252025-12-31USD 3,018,760,0008.0%
Amneal Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-304.2%
Q32025-09-308.3%
Q42025-12-313.8%
Q12026-03-31-11.3%
Amneal Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.86N/A
20232023-12-31USD -0.48-44.6%
20242024-12-31USD -0.38-20.7%
20252025-12-31USD 0.22N/A
Amneal Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3084.8%
Q32025-09-30-89.2%
Q42025-12-311366.7%
Q12026-03-3172.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$722.52M

+3.9%

Gross Profit

$320.11M

+25.1%

Gross Margin

44.31%

N/A

Market Cap

$5.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$673.22K

N/A

Employees

8,500

N/A

Net Income

$62.50M

+412.5%

EBITDA

$176.73M

+14.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$197.66M

+234.0%

Total Debt

$2.70B

+4.5%

Accounts Receivable

$902.65M

+12.8%

Inventory

$641.62M

+6.7%

Long Term Debt

$2.68B

+19.3%

Short Term Debt

$21.49M

-93.6%

Return on Assets

3.46%

N/A

Return on Invested Capital

12.78%

N/A

Free Cash Flow

-$42.59M

-290.2%

Operating Cash Flow

-$28.73M

-487.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
INDVIndivior Pharmaceuticals Inc
$40.53+0.04%
LNTHLantheus Holdings, Inc.
$104.82+1.05%
MIRMMirum Pharmaceuticals, Inc.
$113.03-1.16%
NVSTEnvista Holdings Corp
$26.33+0.61%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%

Questions About AMRX

What is the current price of Amneal Pharmaceuticals?

Amneal Pharmaceuticals is trading at $17.93 per share.

What is the 52-week range for Amneal Pharmaceuticals?

Over the past 52 weeks, Amneal Pharmaceuticals has traded between $7.67 and $18.39.

How much debt does Amneal Pharmaceuticals have?

As of the most recent reporting period, Amneal Pharmaceuticals reported total debt of $2.70B.

How much cash does Amneal Pharmaceuticals have on hand?

Amneal Pharmaceuticals reported $201.83M in cash and cash equivalents in its most recent financial results.

What is Amneal Pharmaceuticals’s dividend yield?

Amneal Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services